Chairman Lim Sung-Ki of Hanmi Pharmaceutical((www.hanmipharm.com) met CEO. John C. Lechleiter of Eli Lilly and Company(www.lilly.com).
Two Chief Executive Officers of both companies met Hanmi Pharmaceutical Headquarter in Songpa-Gu, Seoul on on April 19. Additionally President Lee Gwan-sun President of Hanmi Pharmaceutical and President Paul Henry Huibers of Korea Lilly Company attended.
On last March 19, Hanmi Pharmaceutical and Eli Lilly and Company announced they have entered into an exclusive license and collaboration agreement for the development and commercialization of Hanmi's oral Bruton's tyrosine kinase (BTK) inhibitor, HM71224, for the treatment of autoimmune and other diseases.
By Lee Jae-seung저작권자 © Korea IT Times 무단전재 및 재배포 금지
